<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02513290</url>
  </required_header>
  <id_info>
    <org_study_id>CTBixLo</org_study_id>
    <nct_id>NCT02513290</nct_id>
  </id_info>
  <brief_title>Quality of Life in Patients With Allergic Rhinitis: Clinical Trial With Bilastine or Loratadine</brief_title>
  <acronym>QolRhinitis</acronym>
  <official_title>Quality of Life in Patients With Allergic Rhinitis: a Clinical Trial Comparing the Use of Bilastine Versus Loratadine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidade do Sul de Santa Catarina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universidade do Sul de Santa Catarina</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to verify whether there were differences in health-related
      quality of life of patients with allergic rhinitis treated with bilastine 20 mg compared to
      those treated with loratadine 10 mg.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a prospective randomized double-blinded study, in which patients were recruited from
      august 2013 until august 2014. Outpatients attended in 4 otolaryngology clinics from
      Criciúma, state of Santa Catarina, Brazil were invited to participate of the study. They were
      aged between 18 and 63 years. Seventy-three patient were included, of whom 36 were treated
      with loratadine 10 mg and 37 with bilastine 20 mg with medication administered once a day for
      ten days. The primary outcome was quality of life, assessed by the modified
      Rhinoconjunctivitis Quality of Life Questionnaire (RQLQm), which was applied at baseline and
      after 10 days of treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quality of life in patients with allergic rhinitis</measure>
    <time_frame>10 days</time_frame>
    <description>Application of the modified Rhinoconjunctivitis Quality of Life Questionnaire (RQLQm)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">73</enrollment>
  <condition>Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>Bilastine group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bilastine 20 mg administered once a day for ten days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Loratadine group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Loratadine 10 mg administered once a day for ten days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bilastine</intervention_name>
    <arm_group_label>Bilastine group</arm_group_label>
    <other_name>Alektos</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Loratadine</intervention_name>
    <arm_group_label>Loratadine group</arm_group_label>
    <other_name>Claritin</other_name>
    <other_name>Histadin</other_name>
    <other_name>Loranil</other_name>
    <other_name>Loritil</other_name>
    <other_name>Loralerg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  clinical diagnosis of allergic rhinitis (a typical history of rhinitis symptoms:
             coryza, sneezing, nasal obstruction, nasal itching, and eye symptoms, and
             hypersensitivity tests for specific IgE measured by Radioallergosorbent Test (RAST) or
             skin tests

          -  patients classified as with intermittent rhinitis (symptoms during less than 4 days
             per week) or persistent rhinitis (symptoms during more than 4 days per week) of
             moderate to severe intensity (annoyance impairing the quality and quantity of sleep
             and interfering with daily activities)

        Exclusion Criteria:

          -  pregnancy or breast-feeding;

          -  non-allergic rhinitis (vasomotor, infectious or drug-induced);

          -  known hypersensitivity to antihistamines;

          -  clinical disorders that might affect the assessment;

          -  nasal diseases that could lead to complete blockage or one of the nostrils blockage,
             such as tumors or septal deviation;

          -  therapy with immunotherapy;

          -  use of antihistamines or disodium cromoglycate within the past four weeks;

          -  use of topical or systemic corticosteroids, immunosuppressants or any investigational
             drug within the last two weeks;

          -  use of topical antihistamines or nasal decongestants within the last 48 hours;

          -  use of deposit steroid within the last month.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jane da Silva, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidade do Sul de Santa Catarina</affiliation>
  </overall_official>
  <reference>
    <citation>Juniper EF, Thompson AK, Ferrie PJ, Roberts JN. Validation of the standardized version of the Rhinoconjunctivitis Quality of Life Questionnaire. J Allergy Clin Immunol. 1999 Aug;104(2 Pt 1):364-9.</citation>
    <PMID>10452758</PMID>
  </reference>
  <reference>
    <citation>Carter NJ. Bilastine: in allergic rhinitis and urticaria. Drugs. 2012 Jun 18;72(9):1257-69. doi: 10.2165/11209310-000000000-00000. Review.</citation>
    <PMID>22686617</PMID>
  </reference>
  <reference>
    <citation>Nascimento Silva M, Naspitz C, Solé D. Evaluation of quality of life in children and teenagers with allergic rhinitis: adaptation and validation of the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ). Allergol Immunopathol (Madr). 2001 Jul-Aug;29(4):111-8.</citation>
    <PMID>11674923</PMID>
  </reference>
  <reference>
    <citation>Bachert C, Kuna P, Sanquer F, Ivan P, Dimitrov V, Gorina MM, van de Heyning P, Loureiro A; Bilastine International Working Group. Comparison of the efficacy and safety of bilastine 20 mg vs desloratadine 5 mg in seasonal allergic rhinitis patients. Allergy. 2009 Jan;64(1):158-65. doi: 10.1111/j.1398-9995.2008.01813.x.</citation>
    <PMID>19132976</PMID>
  </reference>
  <reference>
    <citation>Van Cauwenberge P, Juniper EF. Comparison of the efficacy, safety and quality of life provided by fexofenadine hydrochloride 120 mg, loratadine 10 mg and placebo administered once daily for the treatment of seasonal allergic rhinitis. Clin Exp Allergy. 2000 Jun;30(6):891-9.</citation>
    <PMID>10848909</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 29, 2015</study_first_submitted>
  <study_first_submitted_qc>July 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 31, 2015</study_first_posted>
  <last_update_submitted>May 3, 2018</last_update_submitted>
  <last_update_submitted_qc>May 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidade do Sul de Santa Catarina</investigator_affiliation>
    <investigator_full_name>Jane da Silva</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <keyword>quality of life</keyword>
  <keyword>allergic rhinitis</keyword>
  <keyword>bilastine</keyword>
  <keyword>loratadine</keyword>
  <keyword>clinical trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Loratadine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

